Gilead Sciences, Inc.'s Kite cell therapy unit is expanding through external investment, with the company announcing on 20 December that it will acquire privately held Tmunity Therapeutics Inc. for an undisclosed amount to develop next-generation chimeric antigen receptor T-cell (CAR-T) therapies.
The latest deal complements another recent business development deal by Kite with Arcellx, Inc. to co-develop and commercialize an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?